HAWTHORNE, N.Y. --(BUSINESS WIRE)--Aug. 8, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter ended June 30, 2019 . Quarter ended June 30, 2019 Highlights - compared to June 30, 2018 Net sales of $161.3
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jul. 31, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2019 , after the close of market on Thursday August 8, 2019 .
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jun. 21, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO, “Taro”) announced that its Annual Report on Form 20-F for the fiscal year ended March 31, 2019 , filed with the Securities and Exchange Commission (the “SEC”), is available within the Investor
HAWTHORNE, N.Y. --(BUSINESS WIRE)--May 22, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2019 . Quarter ended March 31, 2019 Highlights ─ compared to March 31, 2018 Net sales of
Earnings Call to Discuss Results to be Conducted Thursday, May 23 at 8:00 am ET HAWTHORNE, N.Y. --(BUSINESS WIRE)--May 16, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for year ended March 31, 2019 , on Wednesday, May 22,
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Feb. 6, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and nine months ended December 31, 2018 . Quarter ended December 31, 2018 Highlights ─ compared to December 31, 2017
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jan. 31, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended December 31, 2018 , after the close of market on Wednesday, February 6, 2019 .
HAWTHORNE, N.Y. --(BUSINESS WIRE)--Jan. 15, 2019-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it has completed its $250 million share repurchase program. The company bought back 2,493,378 of its ordinary shares in open market transactions at an average price of $100.28
Special Dividend to be paid on December 28 HAWTHORNE, N.Y. --(BUSINESS WIRE)--Dec. 7, 2018-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) announced today an explanation regarding taxation on the $500 million Special Dividend payable on December 28, 2018 to shareholders
Board of Directors Approves $500 Million Special Dividend HAWTHORNE, N.Y. --(BUSINESS WIRE)--Nov. 5, 2018-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and six months ended September 30, 2018 .
Alerts are e-mailed to you whenever certain new company information is posted to this site.
